Pharmaceuticals

Harmony Biosciences

Harmony Biosciences released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 215.39 M (forecast USD 220.84 M), actual EPS USD 0.5499 (forecast USD 0.6947)

Harmony Biosciences to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 222.68 M, EPS USD 0.7117

Harmony Biosciences released FY2025 Q4 earnings on February 24 Pre-Market EST, actual revenue USD 243.78 M (forecast USD 240.32 M), actual EPS USD 0.3813 (forecast USD 0.8723)

Harmony Biosciences released FY2025 annual earnings on February 24 Pre-Market (EST), actual revenue USD 868.45 M (forecast USD 864.99 M), actual EPS USD 2.71 (forecast USD 3.2001)

Harmony Biosciences Reports Q4 Earnings

Harmony Biosciences to Release FY2025 Q4 Earnings on February 24, 2026, Pre-Market EST; Forecast Revenue USD 240.32M, EPS USD 0.8802

Harmony Biosciences Collaborates with Beacon Biosignals to Advance Narcolepsy Clinical Trials

Harmony Biosciences Announces EPX-100 Phase III Clinical Trial Data for Dravet Syndrome

Needham analyst reiterates buy rating on Harmony Biosciences

Harmony Biosciences Announces Positive Results for Gastro-Resistant Pitolisant Formulation Study

Mizuho Securities Analyst Reiterates Buy Rating on Harmony Biosciences Holdings

Harmony Biosciences released FY2025 Q3 earnings on November 4 Pre-Market (EST), actual revenue USD 239.46 M (forecast USD 222.68 M), actual EPS USD 0.87 (forecast USD 0.6619)

Harmony Biosciences released FY2025 9 Months Earnings on November 4 Pre-Market EST, actual revenue USD 624.68 M, actual EPS USD 2.3299

Harmony Biosciences to Release FY2025 Q3 Earnings on November 4, Pre-Market EST; Forecast Revenue USD 222.68M, EPS USD 0.6742

Harmony Biosciences Raises Revenue Forecast and Reports Wakix Sales Growth

Verma Gives Harmony Biosciences Holdings a Strong Buy Rating

Duncan Reiterates Strong Buy Rating on Harmony Biosciences with Price Target

Harmony Biosciences released FY2025 Q2 earnings on August 5 Pre-Market (EST), actual revenue USD 200.49 M (forecast USD 204.12 M), actual EPS USD 0.6799 (forecast USD 0.7317)

Harmony Biosciences released FY2025 Semi-Annual Earnings on August 5 Pre-Market (EST), actual revenue USD 385.22 M, actual EPS USD 1.46

Harmony Biosciences Reports Strong Earnings and Plans to Expand Product Portfolio

Optimi Health

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

HRMY

Bridge City Capital, LLC, has fully exited its position in Harmony Biosciences Holdings, selling 237,103 shares for an estimated $7.77 million. This sale resulted in a $8.87 million decrease in the fund's position value, which previously represented 2.6% of its AUM. Harmony's stock has underperformed, down 15.4% over the past year. Analysts suggest considering other investment options, as Harmony was not included in a recent list of top stock picks.

nasdaq

Ensign

Sterling Infrastructure

S&P 500

Netflix

NVIDIA

NVIDIA Corporation

A beaten-down biotech just lost a meaningful backer — should you care?

Harmony Biosciences (HRMY) reported a net income of $32.49 million for Q1 2026, down from $45.56 million a year prior. The stock has declined 16.44% over the past 90 days and 19.50% year-to-date. Analysts suggest a fair value of $47.30 per share, indicating it may be undervalued compared to its last close of $30.09. Despite mixed sentiments, the company’s future growth potential remains a topic of discussion among investors.

Simplywall

Assessing Harmony Biosciences (HRMY) Valuation After Softer Earnings But Stronger Free Cash Flow

TRDA

CPRX

Health care stocks experienced a decline late Thursday, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.7%. Notably, Entrada Therapeutics (TRDA) shares plummeted 57% due to disappointing trial results for a drug aimed at Duchenne muscular dystrophy. Iovance Biotherapeutics (IOVA) shares fell over 13% after a narrower-than-expected Q1 loss and missed revenue estimates. Harmony Biosciences (HRMY) shares dropped 5.5% following disappointing Q1 earnings. Conversely, Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after announcing an acquisition by Angelini Pharma valued at approximately $4.1 billion.

Fidelity

Entrada Therapeutics

Catalyst Pharma

Health Care Select Sector SPDR

iShares Biotechnology ETF

Iovance Biotherapeautics

Sector Update: Health Care Stocks Softer Late Afternoon

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences Holdings, raising the price target to $45 due to strong demand for Wakix and reaffirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Despite a one-time spike in R&D spending affecting Q1 2026 earnings, lower administrative costs and healthy core demand for Wakix support the positive outlook. Oppenheimer also maintains a Buy rating with a $72 price target.

Tip Ranks

Oppenheimer

Ami Fadia Reiterates Buy on Harmony Biosciences, Raises Price Target to $45 on Solid Wakix Demand and Reaffirmed 2026 Revenue Guidance

Harmony Biosciences (NASDAQ:HRMY) shares gapped down to $28.95 after reporting weaker than expected earnings of $0.55 EPS, missing estimates of $0.76. Revenue was $215.39 million, below the $220.84 million forecast. Analysts have downgraded the stock's target price, with a consensus rating of "Hold" and an average target price of $42.67. Institutional investors hold 86.23% of the stock, which has a market cap of $1.77 billion and a P/E ratio of 11.17. The company focuses on therapies for rare neurological and endocrine diseases.

Market Beat

Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down  Following Weak Earnings

Earnings Watch

Harmony Biosciences | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 215.39 M

HC Wainwright has issued Q3 2027 EPS estimates for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), forecasting earnings of $1.26 per share. The firm maintains a "Buy" rating with a target price of $55.00. The consensus estimate for the full-year earnings is $3.33 per share. Harmony's recent quarterly earnings were $0.38 per share, missing estimates, but revenue increased by 21.1% year-over-year. Analysts have varied ratings on the stock, with a consensus rating of "Hold" and an average price target of $42.67.

Mizuho Financial Group, Inc.

Mizuho Financial

Bank of America

Truist Financial

UBS Group AG

Deutsche Bank AG

Nasdaq

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Q3 Earnings Estimate for HRMY Issued By HC Wainwright

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 | HRMY Stock News

StockTitan

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 | HRMY Stock News

Harmony Biosciences(HRMY.US)

A beaten-down biotech just lost a meaningful backer — should you care?

Assessing Harmony Biosciences (HRMY) Valuation After Softer Earnings But Stronger Free Cash Flow

Sector Update: Health Care Stocks Softer Late Afternoon

Ami Fadia Reiterates Buy on Harmony Biosciences, Raises Price Target to $45 on Solid Wakix Demand and Reaffirmed 2026 Revenue Guidance

Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down Following Weak Earnings

Harmony Biosciences | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 215.39 M

Q3 Earnings Estimate for HRMY Issued By HC Wainwright

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 | HRMY Stock News